{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"6.210","rs_stock_flag":false,"fiscal_year_end":"2024年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"679,244,132","primaryexch":"香港交易所","ric":"6996.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.0,"inline_upper_strike_price":"","sedol":"BMW9BX8","am":"24.79","iv":"","ew_strike":"","as":"6.000","geographic_focus":null,"incorpin":"開曼群島","etp_baseCur":null,"ew_amt_os":"","bd":"5.950","registrar":"香港中央證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"500","update_time":"2025-09-28 00:06:03.0","lo52":"0.550","shares_issued_date":"2025年9月16日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"梅建明","underlying_ric":"6996.HK","hi52":"8.160","issuer_name":"德琪醫藥有限公司 - B","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"2025年9月26日16:08","aum_date":"","lo":"5.830","mkt_cap":"4.04","f_aum_hkd":null,"ew_sub_per_to":"","ls":"5.950","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"-0.210","aum":"","issued_shares_class_B":null,"vo":"4.14","secondary_listing_flag":false,"listing_date":"2020年11月20日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"德琪醫藥有限公司 - B","nm_s":"德琪醫藥－Ｂ","sym":"6996","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.010","strike_price":"","summary":"德琪醫藥有限公司是一家專注於創新抗腫瘤藥物的亞太地區臨床階段生物製藥公司。該公司主要從事生物科技產品的發現、開發、生產及商業化。該公司的主要產品包括用於治療復發╱難治性多發性骨髓瘤、復發╱難治性瀰漫大B細胞淋巴瘤和非小細胞肺癌的ATG-010(selinexor)及用於治療肝細胞癌和非小細胞肺癌等多種適應症的ATG-008(onatasertib)。該公司主要在亞太地區開展業務。","op":"6.190","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"藥品","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"香港<br/>皇后大道中237號<br/>太興中心第一座<br/>12樓AB單元","pc":"-3.41","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":"RMB","hdr":false,"launch_date":"","hc":"6.160","isin":"KYG039571008","moneyness":""}},"qid":"1759074294807"}
